Insight, China's Pharmaceutical Industry

Company Deals

Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration

XtalPi Inc. (HKG: 2228) and Gan & Lee Pharmaceuticals (SHA: 603087) announced that their jointly...

Others

CrystalO Biopharma Signs Collaboration and Licensing Deal With Almirall for AI‑Driven Skin Disease Drug Discovery, Worth Up to €254.5 Million

Fineline Cube Aug 11, 2026

CrystalO Biopharma Co., Ltd. announced that it has entered into a collaboration and licensing agreement...

Company Deals

Tonghua Golden‑Horse Unit Signs M&A Intent Agreement to Acquire Controlling Stake in 8PLUS1 Pharma

Fineline Cube Aug 11, 2026

Guilin Golden-Horse Innovation Investment Co., Ltd., a wholly owned subsidiary of Tonghua Golden-Horse Pharmaceutical Industry...

Company Deals

Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases

Fineline Cube Aug 11, 2026

Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US‑based Statia Biopharma,...

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Fineline Cube Aug 10, 2026

The Joint Procurement Office published the official winning results for the 12th batch of National...

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Fineline Cube Aug 10, 2026

Sino Medical Sciences Technology Inc. (SHA: 688108) announced that the COMETIU self‑expanding intracranial drug‑eluting stent...

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026

Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million...

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026

Huadong Medicine (SHE: 000963) announced that KIO015 — a novel, patented carboxymethyl chitosan solution for...

Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026

Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary...

Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026

Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary...

Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026

GenFleet Therapeutics (HKG: 2595) announced that “Kylin‑Flight 01,” the registrational Phase 3 clinical trial of...

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026

Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG:...

Legal / IP

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Fineline Cube Aug 10, 2026

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) announced that the U.S. District Court for the District...

Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Fineline Cube Aug 10, 2026

Salubris Pharmaceuticals (SHE: 002294) announced that its self‑developed innovative siRNA drug SAL0195 has been approved by...

Company Drug

Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis

Fineline Cube Aug 10, 2026

Grand Pharmaceutical Group Limited (HKG: 0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC)...

Company Drug

Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients

Fineline Cube Aug 10, 2026

Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) announced that the New Drug Application (NDA) for its core...

Company Drug

Sino Biopharma’s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC

Fineline Cube Aug 10, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib,...

Company Drug

Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly’s GLP-1 Dominance

Fineline Cube Aug 10, 2026

Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced it has submitted a Class 4 Chemical Abbreviated New...

Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026

Daiichi Sankyo Co., Ltd. (TYO: 4568) and Innovent Biologics, Inc. (HKG: 1801) announced an exclusive entrusted promotion...

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026

CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical...

Insight, China's Pharmaceutical Industry

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine

Tempest Therapeutics Signs Strategic Partnership With Senlang to Advance TPST‑4003 In Vivo CAR‑T Candidate in China

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration

CrystalO Biopharma Signs Collaboration and Licensing Deal With Almirall for AI‑Driven Skin Disease Drug Discovery, Worth Up to €254.5 Million

Tonghua Golden‑Horse Unit Signs M&A Intent Agreement to Acquire Controlling Stake in 8PLUS1 Pharma

Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis

Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients

Sino Biopharma’s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC

Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly’s GLP-1 Dominance

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

You Missed

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine